Olverembatinib plus APG-2575 for children with resistant leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new combination of two oral drugs (olverembatinib and APG-2575) for children with a type of leukemia (Ph+ ALL) that has returned or stopped responding to standard treatments. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 years old.
- You must have Ph+ ALL that has come back or not responded to treatment.
- You must have tried at least one TKI and it didn't work or you couldn't tolerate it.
- Your organs (kidneys, liver, heart) must function adequately.
- You must have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
This trial tests a combination of two targeted drugs given before a stem cell transplant for people with a specific type of acute lymphoblastic leukemia (Ph+ ALL) that did not fully respond to initial treatment. The goal is to make the leukemia undetectable before transplant, which may improve outcomes.
This trial tests a combination of three targeted drugs (olverembatinib, venetoclax, and dexamethasone) for people newly diagnosed with a specific type of leukemia called Ph+ ALL. The goal is to see if this combination can help control the disease without needing traditional chemotherapy.
This trial tests a targeted pill (olverembatinib) given after a stem cell transplant to help prevent leukemia from coming back in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It may also be used early if signs of the disease appear.
Hear when a new Refractory Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.